Inovio Pharmaceuticals (INO) is a Plymouth Meeting, Pennsylvania-based commercial-stage biotechnology company developing DNA medicines delivered through its proprietary CELLECTRA electroporation device, focused on HPV-related diseases, cancer, and infectious diseases. The stock rose 9.29% to $1.53 in Tuesday's session, compared with Monday's close of $1.40, a gain of $0.13 that extended a rebound from the post-financing low of $1.07 set on November 6. The move was to the upside. No verified news or fundamental development published before the session explains the advance.
No verified news or fundamental catalyst found ahead of Tuesday's move. The most recent company-specific items — third-quarter results on November 10, an $80.5 million equity offering completed November 9, and a November 11 notice of upcoming investor conference appearances — all predate the session and had already been absorbed by the market. The advance is therefore likely technical and sentiment-driven, consistent with a stock that has repeatedly swung by double-digit percentages since its late-October regulatory decision. In the last 60 completed sessions, 10 moves of 9.3% or more occurred, and the average absolute daily change was roughly 8.5%, so a single-digit rally is close to this stock's normal behavior rather than an outlier. With a thin order book in a sub-$2 share price, modest incremental buying can move the quote quickly.
Underneath the day-to-day noise, the fundamental story that has driven the stock since October 30 remains intact. The FDA granted accelerated approval to VOCERYQ for reducing the frequency of surgical papilloma excisions in adults with recurrent respiratory papillomatosis, making it the company's first marketed product. Inovio has guided investors to a list price of roughly $115,000 per dose, or about $460,000 for the four-dose course, against an estimated U.S. adult population of at least 25,000 patients. Shares are expected to become orderable and shippable about 60 days after approval, with full field deployment in the first quarter of 2027. Sell-side views remain far above the current quote, with targets of $8, $6, and $5, and the November raise extended the company's stated cash runway into late fourth quarter 2027. That combination keeps the name on short lists of traders seeking post-approval biotech launches.
The stock diverged from the broader tape, which opened lower as higher Treasury yields weighed on sentiment; strength in biotechnology and semiconductor shares provided the offsetting pocket of demand. Early volume of about 1.2 million shares in the first hour was in line with the recent pace, well short of the 10.9 million-share average daily figure and far below the 222 million shares traded on November 2, so the move lacked the volume confirmation typical of news-driven gaps. Technically, the advance pushed the shares back toward the $1.50–$1.53 area that capped the November 12 session, a level that now acts as near-term resistance, with support near $1.37, Monday's low. The stock remains roughly 44% below its 52-week high of $2.72 and well above its 52-week low of $0.56.
The scale runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. The score here is 12 out of 100. Verified news was essentially absent: nothing published before Tuesday's opening bell was material relative to a company with a market value near $260 million, and the approval, financing, and conference-notice items were already public and digested. The price move was also unremarkable by the stock's own standards — roughly 1.1 times its typical daily swing, with ten larger or comparable sessions in the past 60. Weak news and a routine move combine into a low score.
Management is scheduled to present at the Jefferies Global Healthcare Conference in London on Wednesday and at the Piper Sandler healthcare conference on December 1, giving investors their next opportunities for commentary on launch readiness and payer engagement. The company has committed to submitting a draft protocol for the required confirmatory study to the FDA by year-end, with final alignment expected around mid-2027, and it plans a European conditional marketing application before the end of 2026. Investors will also track the first product shipments, progress toward reimbursement policies from insurers covering the majority of patients, and fourth-quarter cash burn projected at about $21 million. Key risks include launch execution, the cost of confirming clinical benefit, competition from Precigen's (PGEN) Papzimeos, and the possibility of further capital raising.
Tickeron maintains a curated Trending AI Robots page where hundreds of AI trading bots spanning thousands of tickers are filtered down to the strongest performers under current market conditions. Bots differ by strategy, timeframe, performance metrics, and the symbols they trade, so the featured lineup changes as market conditions shift. Reviewing this section can help traders see which automated approaches are working right now, and it is worth a closer look as part of a broader research routine.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
INO moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend. In 42 of 47 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 89%.
The Momentum Indicator moved above the 0 level on November 18, 2026. You may want to consider a long position or call options on INO as a result. In 49 of 71 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 69%.
The Moving Average Convergence Divergence (MACD) for INO just turned positive on November 02, 2026. Looking at past instances where INO's MACD turned positive, the stock continued to rise in 32 of 40 cases over the following month. The odds of a continued upward trend are 80%.
The 10-day moving average for INO crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 76%.
Following a +4.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where INO advanced for three days, in 180 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The 10-day RSI Indicator for INO moved out of overbought territory on November 03, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In 20 of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
INO broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for INO entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. INO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 63 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (28.741) is normal, around the industry mean (3.596). P/E Ratio (-1.180) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (443.347).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of synthetic vaccines and immune therapies for cancers and infectious diseases
Industry Biotechnology